Malignancy rates and initial management of Thy3 thyroid nodules in a district general hospital: The ‘Reading’ experience
Dilip Nair, Shivanthi Kandiah, Thomas Rourke and 2 more
Endocrinology, Diabetes & Metabolism · 2021
doi:10.1002/edm2.243 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Abstract Background Ultrasound‐guided fine‐needle aspiration cytology is the gold standard for investigating thyroid nodules. Stratifying the Thy3 thyroid nodule risk of malignancy is essential for clinical decision‐making. According to the Royal College of Pathologists Guidance (2016), the rate of malignancy for Thy3a is 5–15% and for Thy3f 15–30%. Our aim was to investigate the malignancy rate and the initial management of Thy3 nodules in our institution. Methods A retrospective review was undertaken of 115 patients with Thy3 cytology results from thyroid fine‐needle aspirations performed between January 2015 and June 2020 at a single centre. A total of 90 out of 115 patients underwent surgery. Results Of the 90 patients, we had a 40% malignant rate (36/90). Specifically, 14 of 34 (41.1%) Thy3a and 22 of 56 (39.2%) Thy3f nodules were malignant. Of the malignant lesions, 52.7% (19/36) were follicular thyroid carcinoma. 58.8% (10/17) of male patients and 35.6% (26/73) of female patients had a malignant histology. Eighteen patients eventually needed a completion thyroidectomy. Conclusion Compared with national data, we showed a higher risk of malignancy in Thy3 nodules in our centre. Our study should encourage other centres to audit their own data. We propose setting up a national Thy3 registry as a basis to promote research in improving preoperative diagnosis of indeterminate thyroid nodules.
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.